Form 8-K - Current report:
SEC Accession No. 0001564590-22-009487
Filing Date
2022-03-10
Accepted
2022-03-10 08:25:30
Documents
12
Period of Report
2022-03-09
Items
Item 2.03: Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant

Document Format Files

Seq Description Document Type Size
1 8-K scyx-8k_20220309.htm   iXBRL 8-K 40827
  Complete submission text file 0001564590-22-009487.txt   168964

Data Files

Seq Description Document Type Size
2 XBRL TAXONOMY EXTENSION SCHEMA scyx-20220309.xsd EX-101.SCH 5693
3 XBRL TAXONOMY EXTENSION LABEL LINKBASE scyx-20220309_lab.xml EX-101.LAB 19431
4 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE scyx-20220309_pre.xml EX-101.PRE 11582
6 EXTRACTED XBRL INSTANCE DOCUMENT scyx-8k_20220309_htm.xml XML 3540
Mailing Address 1 EVERTRUST PLAZA 13TH FLOOR JERSEY CITY NJ 07302-6548
Business Address 1 EVERTRUST PLAZA 13TH FLOOR JERSEY CITY NJ 07302-6548 201-884-5485
SCYNEXIS INC (Filer) CIK: 0001178253 (see all company filings)

EIN.: 562181648 | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-36365 | Film No.: 22727513
SIC: 2834 Pharmaceutical Preparations